Vertaling van "blood pressure lowering treatment " (Frans → Nederlands) :

Deux de ces trois méta-analyses (celle de Staessen et al. et celle de la Blood Pressure Lowering Treatment Trialists’ Collaboration) renforcent l’hypothèse que les résultats divergents (par ex. mortalité cardiovasculaire) observés entre les groupes randomisés dans ces études s’expliquent par les différences de tension artérielle atteinte, même si ces différences de tension artérielle sont parfois faibles.
Twee van de drie metaanalyses (deze van Staessen et al. en deze van de Blood Pressure Lowering Treatment Trialists’ Collaboration) versterken de hypothese dat de verschillen in uitkomst (b.v. cardiovasculaire mortaliteit) tussen de gerandomiseerde groepen in de studies, te verklaren zijn door verschillen in bereikte bloeddruk, ook al zijn deze verschillen in bloeddruk soms gering.

Lancet 2000 ; 356 : 1955-64 (6) Blood Pressure Lowering Treatment Trialists' Collaboration.
Lancet 2000; 356: 1955-64 (6) Blood Pressure Lowering Treatment Trialists' Collaboration.

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis.

D’après A.V. Chobanian et al.: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure.
Naar A.V. Chobanian et al.: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure.

Lancet 363, 2022-2031 (2004) M.A. Weber et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial.
Lancet 363, 2022- 2031 (2004) M.A. Weber et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial.

For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several
For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several randomized trials.1 Effective strategies for the secondary prevention of stroke include

2003; 289: 2534-2544 (11) CHOBANIAN A, BAKRIS G, BLACK H et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure.
2003; 289 :2534-2544 (11) CHOBANIAN A, BAKRIS G, BLACK H et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure.

detection,evaluation, and treatment of high blood pressure.
detection, evaluation, and treatment of high blood pressure.